Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C38681
http://purl.obolibrary.org/obo/NCIT_C38681
|
|---|---|
| Preferred Name | Rilimogene Galvacirepvec |
| Definitions |
A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA. |
|---|---|
| prefLabel | Rilimogene Galvacirepvec
|
| label | Rilimogene Galvacirepvec
|
| PDQ_Closed_Trial_Search_ID | 305934
|
| code | C38681
|
| Has_Target | |
| prefixIRI | NCIT:C38681
|
| in_subset |
See more
See less
|
| Display_Name | Rilimogene Galvacirepvec
|
| Preferred_Name | Rilimogene Galvacirepvec
|
| Contributing_Source | CTRP
|
| Maps_To | Rilimogene Galvacirepvec
|
| CAS_Registry | 1225283-43-1
|
| NSC Number | 717170
|
| NCI_Drug_Dictionary_ID | 305934
|
| Legacy Concept Name | Vaccinia-PSA-TRICOM_Vaccine
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 305934
|
| Semantic_Type |
Pharmacologic Substance
Immunologic Factor
Virus
|
| UMLS_CUI | C1519903
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |